The growing burden of cancer incidence and mortality is one of the most important public health problems with a strong socio-economic impact worldwide. Despite decades of global research efforts, there is still no cure for cancer due to the absence of efficient and specific therapies, which results in high recurrence and relapse rates, thus perpetuating the leading role of cancer in global mortality (Debela et al., 2021). In this context, novel effective anticancer therapies capable of reducing the side effects caused by conventional treatments is one of the biggest challenges towards overcoming the high incidence and prevalence of the disease. In the last years, metal-based anticancer drugs have gained an undisputed role in cancer therapy, as evidenced by the clinical success of platinum-based anticancer drugs. In fact, it is estimated that, in the last decade, more than half of patients receiving anticancer chemotherapy were treated with therapeutic regimens containing platinum complexes (Johnstone et al., 2014). Despite some limitations, such as severe toxic side effects and acquired resistance, their evident clinical success has inspired a growing number of researchers to develop new therapeutic approaches based on metal complexes (Ndagi et al., 2017). These efforts have seen significant advances due to the input of the rational design of metal compounds for cancer treatment, but the high occurrence of multidrug resistance and severe side effects associated with chemotherapy still remain a challenge. As such, new generations of metal compounds with new mechanisms of action, broader spectra and improved anticancer properties are still needed.
The Research Topic “Rational Drug Design of Metal Complexes for Cancer Therapy” highlights several recent developments in the field of metal compounds for cancer therapy. The issue comprises 5 selected peer-reviewed manuscripts (three original research articles and two reviews) covering research on design and synthesis, structure-activity relationships, mechanistic studies regarding biological targets and pathways involved, as well as important applications and recent developments in effect of metal complex in the modulation of the metabolic pathways of cancer. Green et al. report the synthesis and the antiproliferative activity om HCT116, SW480, SiHa and NCI-H460 cells of a series of Os(III)-Ru(II), Rh(III)-Ru(II), Os(II)-Rh(III), Ir(III)-Rh(III), Ir(III)-Ru(II) and Ir(III)-Os(II) heterodimetallic complexes based on a ditopic ligand featuring 2-pyridylimine chelating motifs and organometallic half-sandwich moieties. An innovative combination of approaches is proposed by Castro and co-workers, who evaluate the efficacy of thiopyridinium Zn(II) phthalocyanines (ZnPcs) conjugates for photodynamic therapy (PDT) B16F10 melanoma cells. In this article, the authors describe the photophysical, photochemical, and in vitro photobiological properties of ZnPcs and correlate the number of charge units, and the presence/absence of a-F atoms on the phthalocyanine structure with the PDT efficacy of the complexes. Focusing on the combinatory effect of strategies, Meier-Menches et al. explored the profile of cellular responses and characterized the differentiation–and metal-specific effects of the clinically used combination treatment arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) in acute myeloid leukemia (AML) cells. The authors also investigate the response of the organoruthenium compound plecstatin-1 in combination with the ATRA. An excellent review by HYPERLINK Kou et al. discusses the recent developments on gold complexes as modulators of tumor cell metabolism. The authors discuss the rationale underlying the anti-tumor effects of the gold compounds based on their effects on glucose, protein, and nucleic acid metabolism. Finally, Murillo et al. outline the applications of transition metal complexes as anticancer agents acting through changes in the intracellular redox balance and interaction with redox enzymes.
The editors hope that this research topic will contribute with new and useful information to the progress of research and development of new approaches based on metal complexes for cancer therapy.
Statements
Author contributions
All authors have made a strong, direct, and intellectual contribution to this work and approved it for publication.
Funding
This work was supported by the Fundação para a Ciência e a Tecnologia, IP/MCTES through national funds—UIDB/00100/2020 (CQE), LA/P/0056/2020 (IMS), UIDP/04378/2020 and UIDB/04378/2020 (UCIBIO), LA/P/0140/2020 (i4HB), and project PTDC/QUI-QIN/0146/2020. TM thanks FCT for Scientific Employment Stimulus (CEECIND) Initiative for the project CEECIND/00630/2017 (acknowledging FCT, as well as POPH and FSE-European Social Fund).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Debela D. T. Muzazu S. G. Heraro K. D. Ndalama M. T. Mesele B. W. Haile D. C. et al (2021). New approaches and procedures for cancer treatment: Current perspectives. SAGE open Med.9, 205031212110343. 10.1177/20503121211034366
2
Johnstone T. C. Park G. Y. Lippard S. J. (2014). Understanding and improving platinum anticancer drugs – phenanthriplatin. Anticancer Res.34, 471.
3
Ndagi U. Mhlongo N. Soliman M. E. (2017). Metal complexes in cancer therapy - an update from drug design perspective. Drug Des. devel. Ther.11, 599–616. 10.2147/DDDT.S119488
Summary
Keywords
cancer chemotherapy, inorganic/organometallic, medicinal chemistry, metal-based drug design, drug delivery, mechanism of action, nanomedicine
Citation
Morais TS, Fernandes AR, Baptista PV and Gambino D (2022) Editorial: Rational drug design of metal complexes for cancer therapy. Front. Chem. 10:1035274. doi: 10.3389/fchem.2022.1035274
Received
02 September 2022
Accepted
06 September 2022
Published
20 September 2022
Volume
10 - 2022
Edited and reviewed by
Michael Kassiou, The University of Sydney, Australia
Updates
Copyright
© 2022 Morais, Fernandes, Baptista and Gambino.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tânia S. Morais, tsmorais@ciencias.ulisboa.pt; Alexandra R. Fernandes, ma.fernandes@fct.unl.pt; Pedro V. Baptista, pmvb@fct.unl.pt; Dinorah Gambino, dgambino@fq.edu.uy
This article was submitted to Medicinal and Pharmaceutical Chemistry, a section of the journal Frontiers in Chemistry
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.